Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Adenosine Diphosphate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 known ✓ | P47900 | 9/20 | 0.78 |
| ▸ | P2RY2 known ✓ | P41231 | 3/20 | 0.78 |
| ▸ | ADORA1 known ✓ | P30542 | 1/20 | 0.77 |
| ▸ | PDE4D known ✓ | Q08499 | 1/20 | 0.77 |
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.77 |
| ▸ | SRC | P12931 | 2/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.78 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.78 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.78 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.78 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.78 |
| ▸ | P2RY11 | Q96G91 | 3/20 | 0.77 |
| ▸ | TRPM2 | O94759 | 2/20 | 0.77 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.77 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.77 |
| ▸ | LDHA | P00338 | 1/20 | 0.77 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.77 |
| ▸ | FBP1 | P09467 | 1/20 | 0.77 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adenosine Diphosphate SCHEMBL4734035 | 1.00 | P2RY1 (0.78) | P2RY1P2RY2SRCSMN1; SMN2P2RX1 | |
| Adenosine Diphosphate SCHEMBL30936667 | 0.99 | P2RY1 (0.76) | P2RY1P2RY2SRCSMN1; SMN2P2RX1 | |
| Adenosine Diphosphate SCHEMBL11579601 | 0.99 | P2RY1 (0.76) | P2RY1P2RY2SRCSMN1; SMN2P2RX1 | |
| Adenosine Diphosphate SCHEMBL29803182 | 0.99 | P2RY1 (0.76) | P2RY1P2RY2SRCSMN1; SMN2P2RX1 | |
| Adenosine Triphosphate SCHEMBL30839398 | 0.98 | P2RY1 (0.75) | P2RY1P2RY2SRCSMN1; SMN2P2RX1 | |
| Adenosine Triphosphate SCHEMBL1496269 | 0.98 | P2RY1 (0.75) | P2RY1P2RY2SRCSMN1; SMN2P2RX1 | |
| Adenosine Diphosphate SCHEMBL29444634 | 0.98 | P2RY1 (0.78) | P2RY1P2RY2SRCSMN1; SMN2P2RX1 | |
| Adenosine Diphosphate SCHEMBL28284912 | 0.98 | P2RY1 (0.78) | P2RY1P2RY2SRCSMN1; SMN2P2RX1 | |
| Adenosine Triphosphate SCHEMBL27568797 | 0.96 | P2RY1 (0.73) | P2RY1P2RY2SRCSMN1; SMN2P2RX1 | |
| Adenosine Triphosphate SCHEMBL30819483 | 0.96 | P2RY1 (0.75) | P2RY1P2RY2SRCSMN1; SMN2P2RX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022127326-A1 | PROTEIN AND MULTI-STAGE POROUS METAL-ORGANIC FRAMEWORK COMPLEX, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 华南理工大学 | 2022-06-23 | — | — | WO | claimed |
| US-20260043061-A1 | ENZYMATICALLY MEDIATED REACTIVE CRYSTALLIZATION OF STEVIOL GLYCOSIDES | ARZEDA CORP (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4608984-A2 | ENZYMATICALLY MEDIATED REACTIVE CRYSTALLIZATION OF STEVIOL GLYCOSIDES | Arzeda Corp. (US) | 2025-09-03 | — | — | EP | disclosed |
| CN-119859664-A | Preparation method of glutathione | 浙江工业大学 | 2025-04-22 | — | — | CN | disclosed |
| WO-2024216536-A1 | METHOD FOR PREPARING RIBONUCLEOSIDE OR DERIVATIVE THEREOF, AND BIOLOGICAL ENZYME PREPARATION AND APPLICATION THEREOF | 百瑞全球有限公司 | 2024-10-24 | — | — | WO | disclosed |
| US-20240301460-A1 | ENZYMATIC SYNTHESIS OF 4'-ETHYNYL NUCLEOSIDE ANALOGS | MERCK SHARP & DOHME LLC (US) | 2024-09-12 | — | — | US | disclosed |
| US-12037623-B2 | Enzymatic synthesis of 4′-ethynyl nucleoside analogs | Merck, Sharp & Dohme LLC (US) | 2024-07-16 | — | — | US | disclosed |
| CN-118147269-A | High-flux enzymology normalization analysis method | 中国科学院东北地理与农业生态研究所 | 2024-06-07 | — | — | CN | disclosed |
| CN-118126204-A | Application of haw polysaccharide in preventing and treating non-alcoholic fatty liver and related diseases | 云南农业大学 | 2024-06-04 | — | — | CN | disclosed |
| WO-2024092110-A2 | ENZYMATICALLY MEDIATED REACTIVE CRYSTALLIZATION OF STEVIOL GLYCOSIDES | ARZEDA CORP. (US) | 2024-05-02 | — | — | WO | disclosed |
| US-20230183286-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | NOVARTIS AG (CH) | 2023-06-15 | — | — | US | disclosed |
| US-11466048-B2 | 3′ end caps, 5′ end caps and combinations thereof for therapeutic RNA | NOVARTIS AG (CH) | 2022-10-11 | — | — | US | disclosed |
| US-20220228184-A1 | ENZYMATIC SYNTHESIS OF 4'-ETHYNYL NUCLEOSIDE ANALOGS | MERCK SHARP & DOHME CORP. (US) | 2022-07-21 | — | — | US | disclosed |
| WO-2022127326-A1 | PROTEIN AND MULTI-STAGE POROUS METAL-ORGANIC FRAMEWORK COMPLEX, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 华南理工大学 | 2022-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037623-B2 | Enzymatic synthesis of 4′-ethynyl nucleoside analogs | GALE, ENGASE, RNGTT | P2RY1 3452/4885P2RY2 3719/4885ADORA1 1578/4885 |
| US-20230183286-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | RNGTT, NSUN2, NSUN3 | P2RY1 3340/4885P2RY2 3347/4885ADORA1 1904/4885 |
| US-20260043061-A1 | ENZYMATICALLY MEDIATED REACTIVE CRYSTALLIZATION OF STEVIOL GLYCOSIDES | MGAM, UGDH, UGGT1 | P2RY1 914/4885P2RY2 549/4885ADORA1 3143/4885 |
| US-20240301460-A1 | ENZYMATIC SYNTHESIS OF 4'-ETHYNYL NUCLEOSIDE ANALOGS | GALE, ENGASE, RNGTT | P2RY1 3464/4885P2RY2 3736/4885ADORA1 1571/4885 |
| US-11466048-B2 | 3′ end caps, 5′ end caps and combinations thereof for therapeutic RNA | RNGTT, NSUN3, NSUN2 | P2RY1 2998/4885P2RY2 2954/4885ADORA1 1767/4885 |
| US-20220228184-A1 | ENZYMATIC SYNTHESIS OF 4'-ETHYNYL NUCLEOSIDE ANALOGS | GALE, ENGASE, RNGTT | P2RY1 3464/4885P2RY2 3736/4885ADORA1 1571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.